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oritaka Otsuka, MD, Toshiro Shinke, MD, Dongming Hou, MD, PHD, FACC,
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tlanta, Georgia
bjectives This study sought to determine vasomotor functional responses of conduit coronary
rtery distal to bare-metal stents (BMS), polymer-only stents (POLY), and sirolimus-eluting stents
SES) in a clinically relevant animal model.
ackground Drug-eluting stents (DES) reduce in-stent restenosis, and also affect neointima forma-
ion and vascular remodeling in downstream coronary segments. Whether distal artery vasomotor
unction is also inﬂuenced by DES has not been determined.
ethods Pigs (n  12) received coronary stent implants, and hearts were harvested at 1 month.
rterial segments 15 mm distal to stents were excised and studied in an organ-chamber appara-
us. Endothelium-dependent and endothelium-independent relaxation and contraction to classical
gonists were measured.
esults The SES showed increased lumen area and reduced neointima; abnormal vasomotor func-
ion of conduit arteries distal to SES also was observed. Contraction to endothelin-1 was signiﬁcantly
nhanced for SES compared with both BMS and POLY. Endothelium-dependent relaxation to a maxi-
al dose of substance P was attenuated for SES compared with both BMS and POLY (46  6% vs.
1  3% and 78  3%, respectively, p  0.001). Endothelium-independent relaxation to sodium
itroprusside was potentiated for SES, compared with BMS and POLY (100  5% vs. 69  7% and
7  5%, respectively, p  0.02).
onclusions Stent-based local delivery of sirolimus profoundly inhibited neointima formation but
aused vasomotor dysfunction in distal conduit vessel segments. These observations suggest that
istal coronary vasospasm may be more readily evoked in the presence of DES and contribute to
athophysiological sequela. (J Am Coll Cardiol Intv 2008;1:279–85) © 2008 by the American
ollege of Cardiology Foundation
rom the Saint Joseph’s Translational Research Institute/Saint Joseph’s Hospital of Atlanta, Georgia.anuscript received November 16, 2007; revised manuscript received January 23, 2008, accepted January 29, 2008.
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280evelopment and widespread application of drug-eluting
tents (DES) has provided a novel and efficacious treatment
or coronary artery disease, allowing programmable local-
zed elution of drugs to inhibit neointima formation and
hereby reduce in-stent restenosis compared with bare-
etal stents (BMS) (1–7). However, concerns have arisen
egarding adverse effects of DES in some patients, including
elayed healing, hypersensitivity reactions, and impact of
luted drug on downstream tissue. Delayed or incomplete
e-endothelialization is an important predictor of late stent
hrombosis (LST), which is increasingly apparent for DES
n real-world applications. Prolonged dual antiplatelet ther-
py has been recommended to reduce LST, a rare but
otentially life-threatening complication of DES that has
ecome an increasingly controversial issue for interventional
ardiology (8–10). As a result, the widespread use and
ong-term safety of DES have been questioned.
Several reports have recently
shown that sirolimus-eluting
stents (SES) are associated with
impaired endothelial vasodilator
function in peristent arterial seg-
ments as late as 6 months after
implant (11). On the other
hand, subjects who received
BMS showed normal endothe-
lial function in peristent seg-
ments. Paradoxical vasoconstric-
tion was induced in response to
exercise (12) and pharmacologi-
cal stress (13,14), including se-
vere vasoconstriction in distal
coronary segments. From major
clinical trials, DES have been
found to inhibit neointima for-
mation at the distal stent edge
and in the coronary segment
ownstream to the stent, but have less impact in the
roximal site (15,16); together these observations point to a
umulative downstream watershed impact of upstream-
luted drug compound.
Nitric oxide (NO) released primarily from the vascular
ndothelium plays pivotal roles in coronary vasomotor
unction, inflammation, thrombosis, atherosclerosis, and
rterial neointima formation (17–19). Dysregulation of NO
ynthesis or bioavailability is associated with paradoxical
asoconstriction, procoagulant state, and increased inflam-
ation, and may play a role in LST. Comprehensive in vitro
asomotor function analysis in conduit artery segments
istal to SES implants has not been previously reported.
he purpose of the present study was to assess vasomotor
unction of coronary segments distal to SES in a clinically
bbreviations
nd Acronyms
MS  bare-metal stent(s)
ES  drug-eluting stent(s)
T  endothelin
NOS  endothelial nitric
xide synthase
EL  internal elastic lamina
-NAME  NW-nitro-L-arginine
ethyl ester
ST  late stent thrombosis
GF2  prostaglandin F2
OLY  polymer-only coated
tent(s)
ES  sirolimus-eluting
tent(s)
NP  sodium nitroprussideelevant porcine coronary artery model (20,21). Iethods
ll experiments and animal care conformed to federal
uidelines and were approved by the Institutional Animal
are and Use Committee. Twelve castrated male and
emale Yorkshire hybrid domestic pigs (Sus scrofa) were
sed, and received daily oral antiplatelet medication, with
lopidogrel 300 mg and aspirin 81 mg for 3 days before stent
mplantation then clopidogrel 75 mg and aspirin 81 mg
aily until termination. Body weight was 31  2 kg and 39
2 kg at the times of the stent implant and at 1 month
ollow-up, respectively.
tent implant procedure. Stents were implanted according
o standard procedures. Vessel diameter at the target site
as measured by quantitative coronary angiography. Bare-
etal stents (BMS) (ACS multilink 3.0/28 mm and Penta
ultilink 3.5/28 mm, Guidant, Santa Clara, California),
olymer-only coated stents (POLY) (ChronoFlex AL,
.0/28 mm. ChronoFlex AL is an aliphatic, ether-free,
olycarbonate thermoplastic polymer that belongs to a
amily of biodurable thermoplastic polyurethane elastomers,
ardioTech, Wilmington, Massachusetts), and SES
Cypher, 3.0/23 and 3.5/28 mm, Cordis, Miami, Florida)
ere implanted in 3 coronary arteries per pig by randomized
ssignment to anatomic location. The stent was advanced to
he selected location and deployed by inflation of the
alloon catheter to a pressure appropriate to oversize by
pproximately 15% relative to baseline vessel diameter.
nimals were recovered and returned to routine care.
istology. Three pigs were terminated 1 month post-
tenting; hearts were harvested and perfused with saline and
hen perfusion-fixed with a 5% formalin/1.25% glutaralde-
yde mixture. The next day, the stented left anterior
escending artery, left circumflex artery, and right coronary
rtery were excised. The stented vessels (3 BMS, 3 POLY,
nd 3 SES) were dehydrated in graded ethanol series to
00% then embedded in methyl methacrylate. Sections were
ut from the proximal, middle, and distal stent regions using
heavy-duty microtome and collected on glass slides.
djacent or near-adjacent sections were stained with
ematoxylin-eosin and Verheoff-Masson elastin-trichrome.
istological sections were prepared and evaluated for the
xtent of stent-induced coronary vessel injury and response.
Each section was imaged by charge-coupled device cam-
ra at an appropriate low magnification. Histomorphomet-
ic analysis was performed by computerized planimetry on
roximal, mid, and distal sections. The following measure-
ents were made: neointimal thickness (lumen to each stent
trut), luminal area, internal elastic lamina (IEL) area, and
xternal elastic lamina area. The areas of the neointima and
edia were obtained by subtraction of the lumen area from
he IEL and IEL from external elastic lamina, respectively.
he histological percent area stenosis ([1  (luminal area/EL area)]  100) was calculated.
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281ascular function study. Also at 1 month after stent im-
lant, the remaining 9 pigs were terminated; hearts were
arvested and placed in ice-cold Krebs solution. Coronary
rtery segments beyond 15 mm distal to stent implants were
leaned of loose fat and connective tissue and cut into 4-mm
ong rings (Fig. 1). One ring from each segment (6 BMS, 5
OLY, and 6 SES) was suspended in an individual organ
hamber (Radnoti Glass Technology, Monrovia, Califor-
ia) filled with 17 ml freshly prepared Krebs solution with
he following composition (mM): NaCl 120, MgSO4 1.17,
H2PO4 1.18, NaHCO3 25.0, CaCl2 2.5, KCl 4.7, glucose
.5, and 10 M indomethacin at pH 7.4. The solution was
ontinuously bubbled with 95% O2 and 5% CO2 and
aintained at 37°C. Vascular rings were gradually stretched
o a basal tension of 3 g, which was continuously adjusted
ver approximately 90 min until vessel tension stabilized.
essels were subjected to the same passive tension of 3 g
hroughout the remainder of the study. Krebs buffer was
hanged every 15 min during the equilibration period.
Vessel responsiveness was tested with 40 and 100 mM
Cl. Rings were pre-constricted with a single dose (5 M)
f prostaglandin F2 (PGF2) until they reached a stable
lateau (approximately 7 min). Arterial rings were then
xposed to a series of endothelium-dependent and
ndothelium-independent vasodilators. First, concentration
esponse to substance P (0.01 to 100 pM) and sodium
itroprusside (SNP; 0.001 to 10 M) was determined.
fter incubation with 100 M NW-nitro-L-arginine methyl
ster (L-NAME) (a competitive inhibitor of NO synthase)
or 45 min, substance P concentration response was re-
eated. Rings were then contracted with 0.1 M
Figure 1. Angiography and Macroscopy of Coronary Segments
(A) Coronary angiography 1 month after stent implant in LAD (top arrow);
segments studied were the distal conduit vessel (bottom arrow). (B) Mac-
roscopy at tissue harvest showing the LAD stent (top arrow) and relation
to distal conduit vessel segment (bottom arrows) harvested and analyzed
in the organ chamber apparatus. LAD  left anterior descending artery.ndothelin-1 (ET-1) at the end of each experiment. Vessels
ere washed for 45 min between each serial concentration-
esponse determination. Isometric tension was digitized,
cquired, and analyzed using a Ponemah Tissue Platform
ystem (Gould Instrument System, Valley View, Ohio).
tatistical analysis. Data are presented as mean  standard
rror, and were assessed using one-way analysis of variance
o test for the effect of upstream stent type on each
ependent variable. If a significant treatment effect was
bserved, multiple comparisons using Tukey test were made
o identify between-groups differences. No corrections were
ade for multiple analysis of variance on the same variables
t different concentrations. For certain variables, Student t
ests were used to compare group means. Significance was
stablished at the 95% confidence level (p  0.05).
esults
acroscopic ﬁndings and histomorphometry in stented seg-
ents. Baseline lumen diameter of target coronary seg-
ents was similar among BMS, POLY, and SES groups
2.84  0.12 mm, 2.81  0.08 mm, and 2.75  0.09 mm,
espectively, p  0.806). Angiography showed appropriate
tent deployment without complications in all vessels. No
istal edge dissection or vasospasm was observed during any
tent implant procedure, for any stent type, that might
nfluence subsequent coronary vasomotor function.
At tissue harvest 1 month post-implant, there were no
rossly visible myocardial infarctions. Macroscopic exami-
ation revealed loose fat and connective tissue surrounding
he stented BMS and POLY vessels. Pericoronary tissue
round SES was denser and more difficult to dissect than
MS and POLY stents. These morphologies were not
resent at sites proximal or distal to the stent segment in any
f the stent groups.
Representative histological sections of stented segments
f BMS, POLY, and SES are shown in Figure 2. Neoin-
imal thickness was 0.17  0.04 mm for SES group
ompared with 0.31  0.06 mm for BMS and 0.62  0.13
m for POLY, respectively, p  0.008.
asomotor function distal to stent implants. Contractile
esponses of downstream coronary segments to 40 and 100
M KCl did not differ according to stent type. Baseline
atio of 5 M PGF2-induced contraction to 40-mM
Cl-induced contraction was also similar among groups
0.31  0.05% vs. 0.32  0.07% and 0.40  0.12%, p 
.75). However, in the presence of the NO synthetase
nhibitor L-NAME, contraction to PGF2/40-mM KCl
as potentiated for SES (0.93  0.18% vs. 0.31  0.05%,
 0.008) (Fig. 3A). Contraction to ET-1 compared with
ontraction to 40-mM KCl was greater for SES than for
MS and POLY (1.67  0.15% vs. 1.15  0.03% and 1.17
0.09%, respectively, p  0.021) (Fig. 3B).
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282BMS and POLY arteries relaxed in a dose-dependent
anner to substance P, an endogenous endothelium-
ependent receptor-mediated vasodilator (Fig. 4A). How-
ver, for vessels distal to SES implants the cumulative
oncentration curve was significantly shifted to the right.
he SES vessels showed significantly reduced relaxation at
aximal substance P concentration (46  6% vs. 71  3%
nd 78  3% for SES, BMS, and POLY respectively, p 
.001).
Sodium nitroprusside, an endothelium-independent va-
odilator, induced concentration-dependent relaxation of
oronaries distal to all 3 stent types (Fig. 4B). Unlike
ubstance P, SNP-induced maximum relaxation was higher
or SES than BMS and POLY (100  5% vs. 73  7% and
7  5%, respectively, p  0.02).
After NO blockade with L-NAME, concentration-
ependent relaxation to substance P was significantly
lunted for BMS and POLY to a similar extent (Figs. 5A
nd 5B). For vessel segments distal to SES, relaxation to
ubstance P in the presence of L-NAME was augmented
ompared with BMS and POLY groups (Fig. 5C).
iscussion
n this study, we investigated endothelial function in coro-
ary artery segments distal to BMS, POLY, and SES sites
t 1 month after implantation. Neointimal formation was
arkedly suppressed in SES segments, consistent with
revious reports (22-25). Distal conduit arteries devoid of
Figure 2. Histologic Sections of Stented Arteries
Illustrative histological sections from BMS, POLY, and SES groups. BMS  bare
stent(s).ny direct mechanical injury showed vasomotor dysfunction pistal to SES, but not BMS or POLY stents. Increased
ontractile and endothelium-independent relaxation re-
ponses as well as reduced endothelium-dependent relax-
tion were noted after a period known to comprise the
uration of nearly complete drug release.
The SES elute more than 80% of constituent drug within
0 days. In one study after implantation, about 90% of
irolimus was released into the vessel wall and immediately
djacent tissue, and 7% into remote areas of the heart (26).
his indicates that the amount of sirolimus directly eluted
o distal arterial segments and myocardium via the conduit
rtery luminal circulation was likely to be relatively small,
nd suggests that most of the drug taken up into cardiac
issue was transferred by direct contact with the arterial wall,
hich may have served as a reservoir for subsequent transfer
ia diffusion, or the vasa vasorum. By such a route, the
luted compound could have pharmacological and side
ffects several centimeters from the stent site (27).
Several groups have shown that SES are associated with
asomotor dysfunction in the peristent area (approximately
mm) in vivo at late time points. However, these studies
ere carried out using human patients, with vasomotor
valuation using angiography. Several factors affecting en-
othelial function in vivo could confound these analyses,
ncluding existing arteriosclerotic disease, catheter-based
ntervention, medicinal therapies with direct or indirect
ffects on endothelial function, sirolimus-releasing period,
ealing response, and local hemodynamics. Togni et al. (12)
stent(s); POLY  polymer-only coated stent(s); SES  sirolimus-eluting-metalointed out that testing endothelial function in human
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283atients is technically difficult, and few comparative data are
vailable. There are no comprehensive animal studies ad-
ressing SES-associated endothelial dysfunction published
efore the present report.
In our study, we found that endothelium-dependent
elaxation to substance P was significantly decreased at
igher concentrations distal to SES. Endothelium-
ndependent relaxation of the distal segments was main-
ained in all 3 stent types, and in fact paradoxically increased
t a maximal dose of SNP in SES-stented arteries. Removal
f endothelium has previously been found to enhance
asomotor sensitivity to NO donors, and thereby increased
NP-induced vasorelaxation (28). The NO generation by
ascular endothelium attenuates the NO-donor (SNP) re-
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Figure 3. Contractile Responses of Coronary Segments Distal to Stents
Contractile responses to constriction agonists for coronary arteries distal to
BMS, POLY, and SES stents. (A) In the presence of NW-nitro-L-arginine
methyl ester (L-NAME), contractile response to prostaglandin F2 (PGF2)
was increased for SES (p  0.008). (B) The contractile response to endo-
thelin (ET)-1 was also increased for SES (p  0.021). Abbreviations as in
Figure 2.ponse, and a competitive interaction between endothelialO and SNP was thought responsible for this effect
29,30).
Several groups observed exercise-induced and drug-
nduced vasoconstriction with normal nitroglycerine-
nduced vasodilatation in segments distal to SES 6 months
fter implant in humans (11–14); our findings corroborate
he first result but are at variance with the latter. This
ifference could originate from a variety of mechanisms
ncluding species differences, analytical methods (in vivo
ngiographic vs in vitro organ chamber), and location (distal
tent segment vs approximately 15 mm distal to stent site).
ur results documenting decreased endothelium-dependent
elaxation and increased endothelium-independent relax-
tion distal to Cypher implants support the notion that
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Figure 4. Relaxation Responses of Coronary Segments Distal to Stents
Cumulative concentration–relaxation curves for coronary artery segments
distal to BMS, POLY, and SES. (A) Relaxation to higher concentrations of
endothelium–dependent vasodilator substance P was inhibited in coronary
segments distal to SES compared with BMS and POLY (p  0.05). (B)
Relaxation to the highest concentration of the endothelium-independent
dilator sodium nitroprusside was higher for SES compared with BMS and
POLY (p  0.02). Abbreviations as in Figures 1 and 2.
t
l
s
e
p
t
m
i
c
a
c
s
s
w
t
a
o
e
e
s
p
d
i
g
a
e
v
T
s
s
d
e
s
r
f
m
o
g
n
t
t
m
a
w
a
t
b
S
s
v
a
u
d
a
t
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 3 , 2 0 0 8
J U N E 2 0 0 8 : 2 7 9 – 8 5
Li et al.
Cypher and Distal Coronary Vasomotor Function
284here is decreased NO bioavailability from the endothelial
ayer in the segments of conduit coronary artery distal to the
irolimus-eluting implants. Thus, it appears that SES can
xert very potent effects on adjacent arterial segments,
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Figure 5. Effect of Nitric Oxide Synthase Blockade on Endothelium-
Dependent Relaxation Response of Coronary Segments Distal to Stents
In the presence of nitric oxide synthetase inhibitor L-NAME, relaxations to
endothelium-dependent receptor-mediated vasodilator agonist substance P
were inhibited to a greater degree in BMS (A) than in POLY (B) than in SES
(C) (p  0.05, #p  0.01). Abbreviations as in Figures 2 and 3.articularly distal segments, where it would be anticipated phat drug released from the stents on the luminal aspect
ight enter the circulation at especially high concentrations
n the flow boundary layer, where the tissue interface
onsists of the vascular endothelium.
Contractile responses to KCl and PGF2 were similar
mong the stent types. Contractions to ET-1 were signifi-
antly enhanced for SES compared with BMS and POLY
tents. In the presence of the endothelial nitric oxide
ynthase (eNOS) inhibitor L-NAME, contraction to PGF
as increased. Furthermore, in the presence of L-NAME,
he minimal substance P-induced relaxations in Cypher
rteries were more profoundly blocked than in the absence
f the NOS inhibitor. These data suggest that both endog-
nous vasoconstrictor substances as well as eNOS were
nhanced in conduit vessel segments distal to the Cypher
tent implant. Thus, an augmented eNOS activity may be
resent as a compensatory mechanism to alleviate the
ysfunctional vasomotion.
Sirolimus itself been reported to inhibit endothelial function
n vitro. Mohacsi et al. (31) reported that sirolimus-inhibited
rowth factor induced proliferation of the cultured endothelial
nd smooth muscle cells. Jeanmart et al. (32) also showed
ndothelial dysfunction in porcine coronary arteries with an in
itro model of drug incubation in Krebs-bicarbonate solution.
hey reported that porcine epicardial arteries exposed to
irolimus had severe impairment of relaxant responses to
erotonin and bradykinin, and suggested that sirolimus had a
irect adverse effect on endothelial function. Impairment of
ndothelial recovery may also have adverse long-term impacts
uch as LST, lesion recurrence, and constrictive vascular
emodeling (33,34).
Our results show that although effective to inhibit neointima
ormation, drugs eluted from stents can adversely affect vaso-
otor function of downstream coronary segments. The pattern
f changes we observed for Cypher stents suggests that at any
iven level of an endogenous humoral vasoactive agent, coro-
ary arteries distal to the DES site will constrict more readily
han for sites distal to BMS. This lower set point for contrac-
ion would be anticipated to have adverse effects on distal
yocardial perfusion and regional myocardial function as well
s to limit blood flow velocity and exacerbate nonlaminar flow
ithin the stented segment, potentially increasing thrombotic
nd inflammatory tendencies. Longer-term studies are needed
o verify and elucidate the effect of the drugs on the vascular
ed.
tudy limitations. The small numbers of animal subjects
hould be considered and the statistical analysis of data
iewed accordingly when interpreting these results. We
cknowledge the potential limitations imparted by the
tilization of different stent platforms for each group. The
ifferences in stent material and design may introduce
dditional and potentially confounding variables. In addi-
ion, normal porcine coronary arteries may not necessarily
redict similar effects as in atherosclerotic human vessels.
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285owever, similar studies in normal porcine coronary arteries
ith DES have been used extensively and successfully as the
asis for DES clinical research and development.
onclusions
he SES may cause endothelial and vasomotor dysfunction
f the coronary artery segments distal to implant sites in pig
oronary arteries. This may contribute to increased late
hrombotic adverse events through diverse pathophysiolog-
cal mechanisms. The long-term clinical consequences of
his phenomenon remain to be established.
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